Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis

Table 2 Demographics and results of the included studies

Ref.	No.	Male, n	Age in yr	TIPS success rate, %	Cavernoma, n	1-yr portal vein recanalization rate, %	2-yr portal vein recanalization rate, %	1-yr TIPS patency, %	Encephalopathy rate, %	Survival rate, %	Combined treatment	Follow-up time
Han et al[9]	57	20	50.9 ± 1.6	75	30	100	68.2	79.3	1-yr 25; 2-yr 27	1-yr 86.1; 5-yr 76.7	Anti-coagulation, heparin-warfarin-aspirin	5 yr
Perarnau et al[10]	34	18	58 ± 11	79	19	N/A	N/A	72	6.9	1-yr 80; 4-yr 55	Heparin for 10 d, prolong to 20 d in patients with thrombocytopenia	4 yr
Luca et al[11]	70	47	55 ± 8	100	0	51	81	64.3	1-yr 27; 2-yr 32	1-yr 89; 2-yr 81	N/A	4 yr
Van Ha et al[4]	15	13	53	86.7	4	N/A	N/A	92.3	7.7	76.9	Heparin-warfarin in 2 cases, heparin in 2 cases	Mean 17 mo
Luo et al[1]	37	19	50.78 ± 13.61	100	0	64.9	71.3	91.7	1-yr 16.2; 2-yr 38.5	1-yr 86.5; 2-yr 72.9	Low molecular weight heparin for 3 d, bridge to warfarin for at least 6 mo	2 yr
Wang et al[2]	25	14	47.28 ± 12.36	100	0		N/A	87	N/A	1-yr 96; 3-yr 39.3	Long-term warfarin	3 yr
Lv et al[12]	24	13	49 (46-62)	96	11	87	80	82.6	26.1	1-yr 83.5; 2-yr 73	Thrombolysis in 5 cases, anti-coagulation in 22 cases	2 yr
Wang et al[13]	64	38	54.76	100	4	76.6	N/A	92.2	1-yr 20.3	1-yr 98.4	Anti-coagulation in 31 cases	1 yr
Lakhoo and Gaba[14]	12	5	63	100	0	58.3	N/A	92	N/A	75%	Anti-coagulation in 3 cases	Median 109 d
Modaresi Esfeh and Ansari-Gilani[15]	50	34	55.3 ± 11	100	N/A	68	N/A	N/A	N/A	N/A	N/A	N/A
Zhang et al[16]	11	6	46 ± 9	100	0	81.8	N/A	81.8	18.2	N/A	AngioJet and anti-coagulation	1 yr
Thornburg et al[17]	61	37	58 (median)	98	29	92	N/A	92	18	5-yr 82	N/A	5 yr

N/A: Not applicable; TIPS: Trans-jugular intrahepatic portosystemic shunt.